|
|
|
Q Biomed Inc 's Comment on Competitors and Industry Peers
We operate in highly competitive segments of the biotechnology and biopharmaceutical
markets. We face competition from many different sources, including commercial
pharmaceutical and biotechnology enterprises, academic institutions, government
agencies, and private and public research institutions. Our product candidates,
if successfully developed and approved, will compete with established therapies,
as well as new treatments that may be introduced by our competitors. Many of our
competitors have significantly greater financial, product development, manufacturing
and marketing resources than us. Large pharmaceutical companies have extensive
experience in clinical testing and obtaining regulatory approval for drugs. In
addition, many universities and private and public research institutes are active
in the fields in which we research, some in direct competition with us. We also
may compete with these organizations to recruit management, scientists and clinical
development personnel. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established
companies. New developments, including the development of other biological and
pharmaceutical technologies and methods of treating disease, occur in the pharmaceutical
and life sciences industries at a rapid pace. Developments by competitors may
render our product candidates obsolete or noncompetitive. We will also face competition
from these third parties in recruiting and retaining qualified personnel, establishing
clinical trial sites and patient registration for clinical trials and in identifying
and in-licensing new product candidates.
Our generic SR89 product candidate will compete directly with Metastron® which
is produced by a subsidiary of General Electric Company, a company with a market
capitalization of over $150 billion. Metastron is currently the sole SR89 product
for the treatment of cancer related bone pain, and we may not be able to penetrate
this market sufficiently. General Electric Company may choose to significantly
reduce the cost of Metastron, and we may face further price competition if other
companies choose to produce a generic SR89 product. Such price competition may
cause us to reduce our price and in turn, decrease any revenues we may generate.
*Market share is calculated based on total revenue.
QBIO's vs. Competition, Data
(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)
| COMPANY NAME |
MARKET CAP
(in millions of $) |
REVENUES
(in millions of $) |
INCOME
(in millions of $) |
EMPLOYEES |
| Q Biomed inc |
QBIO |
0.34 |
0.00 |
-7.00 |
8 |
| SUBTOTAL |
0.34 |
0.38 |
-6.88 |
8 |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071
